Over-the-counter drug Study Guide

📖 Core Concepts Over‑the‑Counter (OTC) medicines – drugs that can be bought without a prescription; they are vetted by a regulatory agency for safety and efficacy when used without a doctor’s supervision. Regulatory basis – OTC status is based on the active pharmaceutical ingredient (API) and product strength. Monograph – a class‑specific FDA document that defines standards (ingredients, dosage, labeling) for OTC drugs deemed “generally recognized as safe and effective” (GRAS/E). New Drug Application (NDA) – required for “new medicines” in the U.S.; OTC products may be marketed under an NDA if they don’t fit an existing monograph. Drug‑facts label – mandatory U.S. label showing active ingredients, uses, warnings, directions, and inactive ingredients. International categories – each country uses its own classification system (e.g., Canada’s 4 schedules, Netherlands’ UR/UA/UAD/AV, UK’s POM, Pharmacy Medicine, General Sales List). Transition criteria – a prescription drug can become OTC after 3–6 years of proven safety, low abuse potential, and when the condition doesn’t need direct doctor supervision. Controlled drug – a medication with high abuse risk that remains prescription‑only (e.g., benzodiazepines, strong opioids). --- 📌 Must Remember GRAS/E → OTC drugs that meet a monograph; no NDA needed. U.K. markings: [POM] = Prescription‑Only, [P] = Pharmacy Medicine, no mark = General Sales List. U.S. labeling: “Drug Facts” panel is mandatory for every OTC product. Netherlands categories: UR = prescription‑only UA = pharmacist‑only (OTC on shelves) UAD = pharmacist or drugstore, limited‑risk, on shelves AV = minimal‑risk, sold in general stores. WHAM screening questions for UK Pharmacy Medicines: Who, How long, Are you allergic, Are you taking medication? Typical reclassification timeline: 3–6 years of safe prescription use before OTC switch. --- 🔄 Key Processes U.S. OTC Monograph Review Expert panel evaluates safety/efficacy of a drug class → publishes/updates monograph → products meeting it are GRAS/E → can be marketed OTC. Switching Prescription → OTC Gather post‑marketing safety data → assess abuse potential → ensure condition can be self‑managed → regulatory authority approves re‑classification (usually after 3–6 years). Label Creation (U.S.) Identify active & inactive ingredients → write indications, warnings, directions → format into standardized “Drug Facts” panel → submit for FDA review (if new). --- 🔍 Key Comparisons U.S. vs. U.K. regulation U.S.: FDA (monograph or NDA) + FTC (advertising). U.K.: Human Medicines Regulations 2012; three categories (POM, Pharmacy Medicine, GSL). Netherlands UA vs. UAD UA: pharmacist‑only, sold OTC on pharmacy shelves. UAD: can be sold by pharmacists or drugstores, placed on shelves with limited‑risk items. Prescription‑Only vs. Pharmacy Medicine (U.K.) POM: must have a prescription; pharmacist dispenses. Pharmacy Medicine: no prescription needed but requires pharmacist screening (WHAM). --- ⚠️ Common Misunderstandings “OTC = safe for everyone.” – OTC drugs are safe when used as directed; misuse can still cause harm. All low‑dose codeine is OTC. – Only in some jurisdictions and usually with strict restrictions; many countries keep it prescription‑only. “Monograph” = “Formula.” – A monograph is a regulatory standard, not the chemical formula of a drug. U.K. “General Sales List” = “any drug.” – Only minimal‑risk products (e.g., ibuprofen 200 mg, antihistamines) qualify. --- 🧠 Mental Models / Intuition “Risk → Restriction Ladder” – Higher abuse or safety risk → higher regulatory barrier (Prescription → Pharmacy Medicine → OTC). “Three‑letter code” in the U.K. (POM, P, GSL) tells you instantly how much pharmacist involvement is required. “Monograph = recipe book.” Think of the monograph as a cookbook that tells you which ingredients and steps are approved for a whole class of OTC products. --- 🚩 Exceptions & Edge Cases Low‑dose codeine OTC – Allowed in some countries but often limited by quantity or age restrictions. OTC products that require a pharmacist – UK Pharmacy Medicines and Netherlands UA/UAD categories need pharmacist involvement despite being “over‑the‑counter.” Advertising regulation split (U.S.) – FTC governs OTC ads; FDA governs prescription ads—a rare split that can confuse students. --- 📍 When to Use Which Choosing regulatory pathway (U.S.): If the product fits an existing monograph → use OTC monograph route (no NDA). If it does not fit → submit an NDA. Selecting a sales venue (Netherlands): Minimal‑risk → AV (general stores). Limited‑risk → UAD (pharmacy or drugstore). Higher‑risk but still OTC → UA (pharmacy shelves only). Screening requirement (U.K.): If product is marked [P] → perform WHAM questions before sale. If marked [POM] → prescription needed; no OTC sale. --- 👀 Patterns to Recognize Label wording – “Do not exceed X tablets per day” → indicates a dosage‑related safety limit common in OTC pain relievers. Category naming – Words like “pharmacy‑only,” “prescription‑only,” or “general sales” directly map to regulatory stringency. Monograph updates – Appear after major safety events (e.g., CARES Act modernizing the update process). --- 🗂️ Exam Traps Confusing “OTC” with “no regulation.” – All OTC drugs are still regulated; the difference is the type of regulation (monograph vs. NDA). Assuming all countries treat “OTC” the same. – Look for country‑specific categories (e.g., UA vs. UAD in the Netherlands). Mixing up WHAM with “who is it for.” – WHAM is a specific set of four screening questions; any answer outside those four is not the official list. Believing “GRAS/E” means “completely safe.” – It only means “generally recognized as safe and effective” when used as labeled; misuse still poses risks. ---